Hence, 30% of immunocompetent mice could be cured from ALK+ ALCL by ceritinib (Figs. 6 and 7), and addition of PD-1 blockade (Fig. 7) lead to an increase of this percentage to 55% (p < 0.05, Chi square test for data pooled from Figs. 6 and 7). This evidence concerns the gene ALK and anaplastic large cell lymphoma.